SightGlass Vision Presents New Data on Diffusion Optics Technology Myopia Control
Findings from three SightGlass Vision Diffusion Optics Technology (DOT 0.2) spectacle lenses studies will be presented at the American Academy of Optometry 2023 annual meeting, which opens this week in New Orleans. Individually and collectively, the studies reinforce the performance of the company’s flagship myopia control intervention, which uses thousands of light scattering elements called dots to mimic more natural contrast on the retina—a unique mechanism of action designed to slow myopia progression in children.*
Data from Control of Myopia Using Diffusion Optics Technology Spectacle Lenses: 4-Year Results (CYPRESS) are being presented by Dr. Debbie Laughton on October 11, demonstrating statistically significant slowing of axial length (AL) progression and cycloplegic spherical equivalent refraction (cSER). Expanding on top line findings shared last month from the multi-site study, researchers report that children wearing their DOT 0.2 spectacles full-time continue to show substantial clinical benefit over 48 months.
Among the additional data reported at Academy ’23 is visual performance among CYPRESS participants over the 4-year span. Mean binocular high contrast LogMAR visual acuity (VA) measurements were clinically stable and similar between groups at distance (test -0.09 ± 0.08, control -0.07 ± 0.06) and near (test -0.03 ± 0.14, control -0.04 ± 0.10). Mean monocular low contrast (10%) distance VA showed an improvement over the course of the study (mean change from baseline: test 0.05 ± 0.12, control 0.07 ± 0.11), and mean peripheral VA improved or remained similar in all quadrants, with no significant differences between treatment groups.
The CYPRESS paper has been selected by the Academy as one of the six most newsworthy presentations scheduled for New Orleans. Dr. Laughton will summarize the work during the Academy-hosted Innovations in Vision and Eye Care event on Wednesday, October 11.
A companion study co-developed by esteemed researcher and Professor James Wolffsohn of Aston University assessed the Visual Impact of Diffusion Optics Technology Lenses for Myopia Control. Children (12.2±1.3 years old, range 10-14, 51% female) were randomly assigned to wear DOT 0.2 spectacle lenses (n=27) or single vision lenses (n=24) for 3.5 years across six North American sites. Investigators determined that the DOT 0.2 lens provides an equivalent visual experience to a standard single vision lens, as evaluated through binocular high and low contrast distance visual acuities, near visual acuity, reading speed, contrast sensitivity, stereoacuity and glare measures.
Presented by Dr. Kylvin Ho of C U Vision Optometrists (Vancouver), Real-World Effectiveness of Diffusion Optics Technology (DOT) Spectacle Lenses for Myopia Control in Chinese Canadian Children identified 39 patients who were prescribed the intervention as a monotherapy between October 2020 to December 2022 in an independent practice. After 12 months, mean progression was -0.28 ± 0.32 D in SER (n=39) and 0.15 ± 0.17 mm in AL (n=36). SER progression was limited to -0.25 D or less in 56% of children during the time frame.
Compared to Singapore Cohort Study of the Risk Factors for Myopia (SCORM) data, DOT 0.2 lenses slowed AL progression by 62% (0.24 mm). The 12-month AL elongation was similar to 0.14 mm SCORM-predicted, age-matched emmetropic eye growth (physiological eye growth). The Canadian practice data also aligned with CYPRESS study 12-month outcomes of 0.15 mm AL progression.
Over the last two years, SightGlass Vision’s technology made its commercial debut in several markets, including China, the Netherlands, and Israel, as well as through preliminary market trials in other countries. The company operates as a joint venture of CooperCompanies and EssilorLuxottica.
For more information, visit SightGlassVision.com.